Alnylam Pharmaceuticals (BSP:A1LN34) Total Liabilities : R$19,847 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Alnylam Pharmaceuticals Total Liabilities?

Alnylam Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 was R$19,847 Mil.

Alnylam Pharmaceuticals's quarterly Total Liabilities increased from Jun. 2023 (R$18,495.16 Mil) to Sep. 2023 (R$19,779.19 Mil) and increased from Sep. 2023 (R$19,779.19 Mil) to Dec. 2023 (R$19,846.76 Mil).

Alnylam Pharmaceuticals's annual Total Liabilities increased from Dec. 2021 (R$17,276.29 Mil) to Dec. 2022 (R$19,432.01 Mil) and increased from Dec. 2022 (R$19,432.01 Mil) to Dec. 2023 (R$19,846.76 Mil).

Alnylam Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Alnylam Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Total Liabilities Chart

Alnylam Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

3,925.72

12,300.02

17,276.29

19,432.01

19,846.76

Alnylam Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															19,432.01	19,017.54	18,495.16	19,779.19	19,846.76

Alnylam Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Alnylam Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4741.958	+	(6192.745	+	7990.034
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	922.02	+	0)
	=	19,847

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	18765.646	-	-1081.111
	=	19,847

Alnylam Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4741.958	+	(6192.745	+	7990.034
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	922.02	+	0)
	=	19,847

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	18765.646	-	-1081.111
	=	19,847

Alnylam Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Alnylam Pharmaceuticals (BSP:A1LN34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (BSP:A1LN34) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ALNY:USA ALNY:Mexico DUL:Germany DUL:Germany

Address

675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142

Website

https://www.alnylam.com

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals (BSP:A1LN34) Headlines

No Headlines